- Galderma is projecting a 12% to 14% increase in full-year sales at constant exchange rates for 2025.
- The company expects its core EBITDA margin to remain around 23% at constant exchange rates.
- First-half net sales reached $2.45 billion.
- Core EBITDA for the first half was reported at $555 million, with a margin of 22.7%.
- Galderma attributes its growth to strong performance and substantial investment in significant new product launches.
- The slight uptick in first-half profitability was partly due to a better-than-expected launch of Nemluvio.
- Despite the strong start, Galderma anticipates a slight decrease in underlying profitability in the second half of the year.
- Analyst suggestions include 10 buys, 4 holds, and 1 sell.
“`
A look at Galderma Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Galderma Group AG, a renowned dermatology company, is positioned for strong long-term growth as evidenced by its impressive Smart Scores. With a stellar Growth score of 5 and Momentum score of 5, Galderma is primed to capitalize on market opportunities and sustain upward momentum. The company’s focus on injectable aesthetics, dermatological skincare, and therapeutic dermatology aligns well with consumer demand, indicating potential for continued expansion and profitability.
While Galderma excels in Growth and Momentum, it also demonstrates solid Value and Resilience with scores of 3 in both categories. This suggests that the company is reasonably priced relative to its fundamentals and has the resilience to navigate challenges effectively. Although the Dividend score is 2, Galderma‘s overall outlook remains robust, underpinned by its strong market position and diversified offerings in the global dermatology market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
